Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Predicting MM progression

Mark Bustoros, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses how the use of genomic predictors in multiple myeloma (MM) allows for the greater stratification of patients and thus provides clinicians with an increased capacity to predict who is most likely to progress. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.